In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations.
Where this comes from
- Record sourced from PubMed, PMID 37665985.
- Also identified by DOI 10.7326/J23-0063.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. <b>Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts.</b> N Engl J Med. 2023;389;205-214.37272521.
Medical subject headings
- Bronchodilator Agents
- Pulmonary Disease, Chronic Obstructive